| 产品名称 | PCI-24781 (CRA-024781) - Deacetylase - Inhibitors / Activators |
| 产品货号 | 27769-1 |
| 产品价格 | 现货询价，电话：010-67529703 |
| 产品规格 | 10 mg |
| 产品品牌 | bpsbioscience |
| 产品概述 | |
| 产品详情 |
MW: 397.4 Da
CAS Registry #: 783355-60-2
Formula: C21H23N3O5
Target: HDAC
Background: PCI-24781 is a pan-HDAC inhibitor that shows antitumor activity in vitro and in vivo preclinically and is under evaluation in phase I clinical trials for cancer, particularly B-cell lymphoma. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-?B mechanisms in Hodgkin lymphoma and non-Hodgkin lymphoma cell lines.
Description: PCI-24781 (also known as CRA-024781) is a novel, broad spectrum inhibitor of HDACs that shows antitumor activity in vitro. PCI-24781 primarily targets HDAC1 (Ki = 7 nM). It also exhibits modest potenty toward HDACs 2, 3, 6, and 10 and greater than 40-fold selectivity against HDAC8.
Synonym(s): PCI-24781; CRA-024781; Abexinostat
Biological Activity: PCI-24781 inhibited pure recombinant HDAC1 with a Ki of (Ki = 7 nM), as well as HDAC2, HDAC3/SMRT, HDAC6, HDAC8, and HDAC10 in the nanomolar range. Antitumor activity of PCI-24781 was observed in all 10 tumor cell lines tested, with GI50% values ranging from 0.15 to 3.09 µM.
Solubility: Soluble in DMSO
Storage / Stability: Store at or below –20°C. Solid form is stable at least 12 months from date of receipt, when stored as directed. Do not store aqueous solutions for more than one day. Reference(s): 1. Buggy JJ, et al. Mol Cancer Ther, 2006, 5(5), 1309-1317.
2. Bhalla S, et al. Clin Cancer Res, 2009, 15(10), 3354-3365. Scientific Category: Deacetylase Inhibitor
Product Type: Inhibitor
Data shown is lot-specific. Contact us for specific information on other lots.
Quality Assurance
|
| 产品资料 |
